Live attenuated vaccines against pertussis

References

• Crowcroft NS, Stein C, Duclos P, Birmingham M. How best to estimate the global burden of pertussis ? Lancet Infect Dis 2003;3:413-18
   PubMed Web of Science ®Google Scholar
• Cherry JD. Epidemic pertussis in 2012. The resurgence of a vaccine-preventable disease. N Engl J Med 2012;367:785-7
   PubMed Web of Science ®Google Scholar
• WHO. Global routine vaccination coverage 2011;Wkly Epidemiol Rec 2012;44:432-5
   Google Scholar
• Storsaeter J, Wolter J, Locht C. Pertussis vaccines. In: Bordetella Molecular Microbiology. Locht C, editors. Horizon Press; 2007. pp 245-88
   Google Scholar
• Cody CL, Baraff LJ, Cherry JD, et al. Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children. Pediatrics 1981;68:650-60
   PubMed Web of Science ®Google Scholar
• Sheridan SL, Ware RS, Grimwood MB, Lambert SB. Number and order of whole cell pertussis vaccine in infancy and disease protection. J Am Med Assoc 2012;308:454-6
   PubMed Web of Science ®Google Scholar
• Witt MA, Katz PH, Witt DJ. Unexpectedly limited durability of immunity following acellular pertussis vaccination in preadolescents in a North American outbreak. Clin Infect Dis 2012;54:1730-5
   PubMed Web of Science ®Google Scholar
• WHO. Meeting of the strategic advisory group of experts on immunization, April 2014 – conclusions and recommendations. Wkly Epidemiol Rec 2014;89:221-36
   PubMedGoogle Scholar
• Locht C, Mielcarek N. New pertussis vaccination approaches: en route to protect newborns? FEMS Immunol Med Microbiol 2012;66:121-33
   PubMed Web of Science ®Google Scholar
• Skowronski DM, Janjua NZ, Tsafack EPS, et al. The number needed to vaccinate to prevent infant pertussis hospitalization and death through parent cocoon immunization. Clin Infect Dis 2012;54:318-27
   PubMed Web of Science ®Google Scholar
• Munoz FM, Bond NH, Maccato M, et al. Safety and immunogenicity of tetanus diphtheria and acellular pertussis (Tdap) immunization during pregnancy in mothers and infants. A randomized clinical trial. J Am Med Assoc 2014;311:1760-9
   PubMed Web of Science ®Google Scholar
• Wood N, McIntyre P, Marshall H, Roberton D. Acellular pertussis vaccine at birth and one month induces antibody responses by two months of age. Pediatr Infect Dis J 2010;29:209-15
   PubMed Web of Science ®Google Scholar
• Gordon J, Hood R. Whooping cough and its epidemiological anomalies. Prev Med Epidemiol 1951;222:333-61
   Google Scholar
• Cherry JD. Pertussis in the preantibiotic and prevaccine era, with emphasis on adult pertussis. Clin Infect Dis 1999;28(Suppl 2)):S107-11
   Google Scholar
• Luttinger P. The epidemiology of pertussis. Am J Dis Child 1916;12:290-315
   Google Scholar
• Fales WT. The age distribution of whooping cough, measles, chicken pox, scarlet fever, and diphtheria in various areas in the United States. Am J Hyg 1928;8:759-99
   Google Scholar
• Mannderstedt G. Pertussis in adults. J Pediat 1934;5:596-600
   Google Scholar
• Wirsing von König CH, Postels-Multani S, Bock HL, Schmitt HJ. Pertussis in adults: frequency of transmission after household exposure. Lancet 1995;346:1326-9
   PubMed Web of Science ®Google Scholar
• Final Pertussis Surveillance Report. Centers for Disease Control and Prevention, 2014. http://www.cdc.gov/pertussis/surv-reporting.html.)
   Google Scholar
• De Serres G, Shadmani R, Duval B, et al. Morbidity of pertussis in adolescents and adults. J Infect Dis 2000;182:174-9
   PubMed Web of Science ®Google Scholar
• Ridda I, Yin JK, King C, et al. The importance of pertussis in older adults: a growing case for reviewing vaccination strategy in the elderly. Vaccine 2012;30:6745-52
   PubMed Web of Science ®Google Scholar
• Wendelboe AM, Van Rie A, Salmaso S, Englund JA. Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J 2005;24:S58-61
   PubMedGoogle Scholar
• Versteegh FG, Schellekens JF, Nagelkerke AF, Roord JJ. Laboratory-confirmed reinfections with Bordetella pertussis. Acta Paediatr 2002;91:95-7
   PubMed Web of Science ®Google Scholar
• Hallander HO, Nilsson L, Gustafsson L. Is adolescent pertussis vaccination preferable to natural booster infections ? Exp Rev Clin Pharmacol 2011;4:705-11
   PubMedGoogle Scholar
• Lavine JS, Bjornstad ON. Friesleben de Blasio, Storsaeter J. Short-lived immunity against pertussis, age-specific routes of transmission, and utility of a teenage booster vaccine. Vaccine 2012;30:544-51
   PubMedGoogle Scholar
• Wearing HJ, Rohani P. Estimating the duration of pertussis immunity using epidemiological signatures. PLoS Pathog 2009;5:e1000647
   PubMed Web of Science ®Google Scholar
• Carollo M, Pandolfi E, Tozzi AE, et al. Humoral and B-cell memory responses in children five years after pertussis acellular vaccine priming. Vaccine 2014;32:2093-9
   PubMed Web of Science ®Google Scholar
• Cherry JD, Beer T, Chartrand SA, et al. Comparison of values of antibody to Bordetella pertussis antigens in young German and American men. Clin Infect Dis 1995;20:1271-4
   PubMed Web of Science ®Google Scholar
• Fine PE, Clarkson JA. The recurrence of whooping cough: possible implications for assessment of vaccine efficacy. Lancet 1982;1:666-9
   PubMed Web of Science ®Google Scholar
• Broutin H, Viboud C, Grenfell BT, et al. Impact of vaccination and birth rate on the epidemiology of pertussis: a comparative study in 64 countries. Proc Biol Sci 2010;277:3239-45
   PubMed Web of Science ®Google Scholar
• Long SS, Lischner HW, Deforest A, Clark JL. Serologic evidence of subclinical pertussis in immunized children. Pediatr Infect Dis J 1990;9:700-5
   PubMed Web of Science ®Google Scholar
• Warfel JM, Zimmerman LI, Merkel TJ. Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model. Proc Natl Acad Sci USA 2014;111:787-92
   PubMed Web of Science ®Google Scholar
• Huang CC, Chen PM, Kuo JK, et al. Experimental whooping cough. N Engl J Med 1962;266:105-11
   PubMed Web of Science ®Google Scholar
• Roberts M, Maskell D, Novotny P, Dougan G. Construction and characterization in vivo of Bordetella pertussis aroA mutants. Infect Immun 1990;58:732-9
   PubMed Web of Science ®Google Scholar
• Cornford-Nairns R, Daggard G, Mukkur T. Construction and preliminary immunobiological characterization of a novel, non-reverting, intranasal live attenuated whooping cough vaccine candidate. J Microbiol Biotechnol 2012;22:856-65
   PubMed Web of Science ®Google Scholar
• Mielcarek N, Debrie AS, Raze D, et al. Live attenuated B. pertussis as a single-dose nasal vaccine against whooping cough. PLoS Pathog 2006;2:e65
   PubMed Web of Science ®Google Scholar
• de Jong MF. Prevention of atrophic rhinitis in piglets by means of intranasal administration of a live non-AR-pathogenic Bordetella bronchiseptica vaccine. Vet Q 1987;9:123-33
   PubMed Web of Science ®Google Scholar
• Lehar C, Jayappa H, Erskine J, et al. Demonstration of 1-year duration of immunity for attenuated Bordetella bronchiseptica vaccines in dogs. Vet Ther 2008;9:257-62
   PubMedGoogle Scholar
• Parkhill J, Sebaihia M, Preston A, et al. Comparative analysis of the genome sequences of Bordetella pertussis, Bordetella parapertussis and Bordetella bronchiseptica. Nat Genet 2003;35:32-40
   PubMed Web of Science ®Google Scholar
• Bey RF, Shade FJ, Goodnow RA, Johnson RC. Intranasal vaccination of dogs with live avirulent Bordetella bronchiseptica: correlation of serum agglutination titer and the formation of secretory IgA with protection against experimentally induced infectious tracheobronchitis. Am J Vet Res 1981;42:1130-2
   PubMed Web of Science ®Google Scholar
• Hoiseth SK, Stocker BAD. Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines. Nature 1981;291:238-9
   PubMed Web of Science ®Google Scholar
• Verma NK, Lindberg AA. Construction of aromatic dependent Shigella flexneri 2a live vaccine candidate strains: deletion mutations in the aroA and the aroD genes. Vaccine 1991;9:6-9
   PubMedGoogle Scholar
• Locht C, Antoine R, Jacob-Dubuisson F. Bordetella pertussis, molecular pathogenesis under multiple aspects. Curr Opin Microbiol 2001;4:82-9
   PubMed Web of Science ®Google Scholar
• Pittman M. The concept of pertussis as a toxin-mediated disease. Pediatr Infect Dis 1984;3:467-86
   PubMedGoogle Scholar
• Melvin JA, Scheller EV, Miller JF, Cotter PA. Bordetella pertussis pathogenesis: current and future challenges. Nat Rev Microbiol 2014;12:274-88
   PubMed Web of Science ®Google Scholar
• Locht C, Coutte L, Mielcarek N. The ins and outs of pertussis toxin. FEBS J 2011;278:4668-82
   PubMed Web of Science ®Google Scholar
• Locht C, Antoine A. A proposed mechanism of ADP-ribosylation catalysed by the pertussis toxin S1 subunit. Biochimie 1995;77:333-40
   PubMed Web of Science ®Google Scholar
• Feunou PF, Ismaili J, Debrie AS, et al. Genetic stability of the live attenuated Bordetella pertussis vaccine candidate BPZE1. Vaccine 2008;26:5722-7
   PubMed Web of Science ®Google Scholar
• Mielcarek N, Debrie AS, Mahieux S, Locht C. Dose response of attenuated Bordetella pertussis BPZE1-induced protection in mice. Clin Vaccine Immunol 2010;17:317-24
   PubMedGoogle Scholar
• Hellwig SM, van Spriel AB, Schellekens JF, et al. Immunoglobulin A-mediated protection against Bordetella pertussis infection. Infect Immun 2001;69:4846-50
   PubMed Web of Science ®Google Scholar
• Feunou PF, Kammoun H, Debrie AS, et al. Long-term immunity against pertussis induced by a single nasal administration of live attenuated B. pertussis BPZE1. Vaccine 2010;28:7047-53
   PubMed Web of Science ®Google Scholar
• Skerry CM, Mahon BP. A live, attenuated Bordetella pertussis vaccine provides long-term protection against virulent challenge in a murine model. Clin Vaccine Immunol 2011;18:187-93
   PubMedGoogle Scholar
• Skerry CM, Cassidy JP, English K, et al. A live attenuated Bordetella pertussis candidate vaccine does not cause disseminating infection in gamma interferon receptor knockout mice. Clin Vaccine Immunol 2009;16:1344-51
   PubMedGoogle Scholar
• Janda WM, Santos E, Stevens J, et al. Unexpected isolation of Bordetella pertussis from a blood culture. J Clin Microbiol 1994;32:2851-3
   PubMedGoogle Scholar
• Mahon BP, Sheahan BJ, Griffin F, et al. Atypical disease after Bordetella pertussis respiratory infection of mice with targeted disruptions of interferon-gamma receptor or immunoglobulin µchain genes. J Exp Med 1997;186:1843-51
   PubMedGoogle Scholar
• Thorstensson R, Trollfors B, Al-Tawil N, et al. A phase I clinical study of a live attenuated Bordetella pertussis vaccine – BPZE1; a single centre, double-blind, placebo-controlled, dose-escalating study of BPZE1 given intranasally to healthy adult male volunteers. PLoS One 2014;9:e83449
   PubMed Web of Science ®Google Scholar
• Watanabe M, Nagai M. Reciprocal protective immunity against Bordetella pertussis and Bordetella parapertussis in a murine model of respiratory infection. Infect Immun 2001;69:6981-6
   PubMed Web of Science ®Google Scholar
• He Q, Viljanen MK, Arvilommi H, et al. Whooping cough caused by Bordetella pertussis and Bordetella parapertussis in an immunized population. JAMA 1998;280:635-7
   PubMed Web of Science ®Google Scholar
• David S, van Furth R, Mooi FR. Efficacies of whole cell and acellular pertussis vaccines against Bordetella parapertussis in a mouse model. Vaccine 2004;22:1892-8
   Google Scholar
• Feunou PF, Bertout J, Locht C. T- and B-cell-mediated protection induced by novel, live attenuated pertussis vaccine in mice. Cross protection against parapertussis. PLoS One 2010;5: e10178
   PubMedGoogle Scholar
• Wolfe DN, Goebel EM, Bjornstad ON, et al. The O antigen enables Bordetella parapertussis to avoid Bordetella pertussis-induced immunity. Infect Immun 2007;75:4972-9
   PubMedGoogle Scholar
• Goebel EM, Wolfe DN, Elder K, et al. O antigen protects Bordetella parapertussis from complement. Infect Immun 2008;76:1774-80
   PubMed Web of Science ®Google Scholar
• Goebel EM, Zhang X, Harvill ET. Bordetella pertussis infection or vaccination substantially protects mice against B. bronchiseptica infection. PLoS One 2009;4:e6778
   PubMed Web of Science ®Google Scholar
• Kammoun H, Feunou PF, Foligne B, et al. Dual mechanism of protection by live attenuated Bordetella pertussis BPZE1 against Bordetella bronchiseptica in mice. Vaccine 2012;30:5864-70
   PubMedGoogle Scholar
• Woolfrey BF, Moody JA. Human infections associated with Bordetella bronchiseptica. Clin Microbiol Rev 1991;4:243-55
   PubMed Web of Science ®Google Scholar
• Gueirard P, Weber C, Le Coustumier A, Guiso N. Human Bordetella bronchiseptica infection related to contact with infected animals: persistence of bacteria in host. J Clin Microbiol 1995;33:2002-6
   PubMedGoogle Scholar
• Li R, Lim A, Phoon MC, et al. Attenuated Bordetella pertussis protects against highly pathogenic influenza A viruses by dampening the cytokine storm. J Virol 2010;84:7105-13
   PubMedGoogle Scholar
• Schnoeller C, Roux X, Sawant D, et al. Attenuated Bordetella pertussis vaccine protects against respiratory syncytial virus disease via an IL-17-dependent mechanism. Am J Respir Crit Care Med 2014;189:194-202
   PubMed Web of Science ®Google Scholar
• Fedele G, Bianco M, Debrie AS, et al. Attenuated Bordetella pertussis vaccine candidate BPZE1 promotes human dendritic cell CCL21-induced migration and drives a Th1/Th17 response. J Immunol 2011;186:5388-96
   PubMed Web of Science ®Google Scholar
• Ennis DP, Cassidy JP, Mahon BP. Prior Bordetella pertussis infection modulates allergen priming and the severity of airway pathology in a murine model of allergic asthma. Clin Exp Allergy 2004;34:1488-97
   PubMedGoogle Scholar
• Kavanagh H, Noone C, Cahill E, et al. Attenuated Bordetella pertussis vaccine strain BPZE1 modulates allergen-induced immunity and prevents allergic pulmonary pathology in a murine model. Clin Exp Allergy 2010;40:933-41
   PubMedGoogle Scholar
• Li R, Cheng C, Chong SZ, et al. Attenuated Bordetella pertussis BPZE1 protects against allergic airway inflammation and contact dermatitis in mouse models. Allergy 2012;67:1250-8
   Google Scholar
• Netea MG, Quintin J, van der Meer JWM. Trained immunity: a memory for innate host defense. Cell Host Microb 2011;9:355-61
   PubMed Web of Science ®Google Scholar
• Benn CS, Netea MG, Selin LK, Aaby P. A small jab – a big effect: nonspecific immunomodulation by vaccines. Trends Immunol 2013;34:431-9
   PubMed Web of Science ®Google Scholar
• Aaby P, Benn C, Nielsen J, et al. Testing the hypothesis that diphtheria-tetanus-pertussis vaccine has negative non-specific and sex-differential effects on child survival in high-mortality countries. BMJ Open 2012;2:e000707
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Soares-Weiser K, Reingold A. Systematic review of the non-specific effects of BCG, DTP and measles containing vaccines. Available from: www.who.int/immunization/sage/meetings/2014/april/3_NSE_Epidemiology_review_Report_to_SAGE_14_Mar_FINAL.pdf?ua=1
   Google Scholar
• Flanagan KL, Klein SL, Skakkebaek NE, et al. Sex differences in the vaccine-specific and non-targeted effects of vaccines. Vaccine 2011;29:2349-54
   PubMed Web of Science ®Google Scholar
• Mukkur T, Richmond P. Development of affordable effective vaccines against whooping cough for the developing world. J Vaccines Vaccin 2012;3: 1000e106
   Google Scholar
• Poolman JT, Hallander H, Halperin SA. Pertussis vaccines: where to now? Expert Rev Vaccines 2011;10:1497-500
   PubMed Web of Science ®Google Scholar
• Shahin RD, Amsbaugh D, Leef MD. Mucosal immunization with filamentous hemagglutinin protects against Bordetella pertussis respiratory infection. Infect Immun 1992;60:1482-8
   PubMedGoogle Scholar
• Berstad AKH, Holst J, Froholm LO, et al. A nasal whole-cell pertussis vaccine induces specific systemic and cross-reactive mucosal antibody responses in human volunteers. J Med Microbiol 2000;49:157-63
   PubMed Web of Science ®Google Scholar
• Mutsch M, Zhou W, Rhodes P, et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell’s palsy in Switzerland. N Engl J Med 2004;350:896-903
   PubMed Web of Science ®Google Scholar
• Holmgren J, Svennerholm AM. Vaccines against mucosal infections. Curr Opin Immunol 2012;24:343-53
   PubMed Web of Science ®Google Scholar
• Locht C. Live bacterial vectors for intranasal delivery of protective antigens. Pharm Sci Technol Today 2000;4:121-8
   Google Scholar
• Mielcarek N, Riveau G, Remoue F, et al. Homologous and heterologous protection after single intranasal administration of live attenuated recombinant Bordetella pertussis. Nat Biotechnol 1998;16:454-7
   PubMed Web of Science ®Google Scholar
• Coppens I, Alonso S, Antoine R, et al. Production of Neisseria meningitidis transferrin-binding protein B by recombinant Bordetella pertussis. Infect Immun 2001;69:5440-6
   PubMedGoogle Scholar
• Reveneau N, Alonso S, Jacob-Dubuisson F, et al. Tetanus toxin fragment C-specific priming by intranasal infection with recombinant Bordetella pertussis. Vaccine 2001;20:926-33
   PubMedGoogle Scholar
• Alonso S, Willery E, Renauld-Mongenie G, Locht C. Production of nontypeable Haemophilus influenzae HtrA by recombinant Bordetella pertussis with the use of filamentous hemagglutinin as a carrier. Infect Immun 2005;73:4295-301
   PubMed Web of Science ®Google Scholar
• Ho SY, Chua SQ, Foo DG, et al. Highly attenuated Bordetella pertussis strain BPZE1 as a potential live vehicle for delivery of heterologous vaccine candidates. Infect Immun 2008;76:111-19
   PubMedGoogle Scholar
• Li R, Lim A, Ow ST, et al. Development of live attenuated Bordetella pertussis strains expressing the universal influenza vaccine candidate M2e. Vaccine 2011;29:5502-11
   PubMedGoogle Scholar
• Kammoun H, Roux X, Raze D, et al. Immunogenicity of live attenuated B. pertussis BPZE1 producing the universal influenza vaccine candidate M2e. PLoS ONE 2013;8:e59198
   PubMed Web of Science ®Google Scholar
• Feunou PF, Kammoun H, Debrie AS, Locht C. Heterologous prime-boost immunization with live attenuated B. pertussis BPZE1 followed by acellular pertussis vaccine in mice. Vaccine 2014;32:421-8
   Google Scholar